Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ibrahim C, Haznedaroğlu"'
Publikováno v:
Turkish Journal of Hematology, Vol 41, Iss 1, Pp 59-60 (2024)
Externí odkaz:
https://doaj.org/article/2e52d4efd6104db79763e04856a37733
Autor:
Hayri Canbaz, Ufuk Oğuz İdiz, Hayriye Cankar Dal, Fatih Kacıroğlu, Seher Taş, Hikmet Can Çubukçu, Attila Bestemir, Murat Gülşen, İstemi Taha Polat, Abubekir Laloğlu, İbrahim Hakkı Tor, Ekrem Akkurt, Utku Ateş, İsmail Reisli, Esin Koç, Ahmet Cağkan İnkaya, Musa Karakükçü, Mustafa Ceylan, İbrahim C. Haznedaroğlu, Haluk Akın
Publikováno v:
Turkish Journal of Hematology, Vol 39, Iss 4, Pp 222-229 (2022)
Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC
Externí odkaz:
https://doaj.org/article/917cd3544b814466820c77dd6ad17791
Autor:
Rafiye Çiftçiler, Hakan Göker, Haluk Demiroğlu, Salih Aksu, Nilgün Sayınalp, İbrahim C. Haznedaroğlu, Ümit Yavuz Malkan, Yahya Büyükaşık, Osman Özcebe
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 4, Pp 256-262 (2020)
Objective: Multiple myeloma (MM) associated with extramedullary (EM) plasmacytoma has a poor therapeutic response and poor outcomes when treated with conventional chemotherapy. EM plasmacytoma is divided into two groups: the first group comprises tum
Externí odkaz:
https://doaj.org/article/03ddb2e8f8e54a4589b8220efc28125a
Autor:
Rafiye Çiftçiler, İbrahim C. Haznedaroğlu, Nilgün Sayınalp, Osman Özcebe, Salih Aksu, Haluk Demiroğlu, Hakan Göker, Ümit Yavuz Malkan, Yahya Büyükaşık
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 2, Pp 116-120 (2020)
Objective: The prognosis of patients with acute myeloid leukemia (AML) is affected by factors that are both patient- and diseasespecific. The aim of this study is to evaluate the impact of early versus late platelet and neutrophil recovery after indu
Externí odkaz:
https://doaj.org/article/7893300b6f3e4fc39cc5991c21103df8
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 1, Pp 42-47 (2020)
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be manageable with tyrosine kinase inhibitor (TKI) drugs. The aim of TKI drug treatment is to provide age- and sex-matched d
Externí odkaz:
https://doaj.org/article/d401534f053c4293b22bc2a0cd0405f3
Publikováno v:
Turkish Journal of Hematology, Vol 34, Iss 1, Pp 93-98 (2017)
Objective: Ankaferd hemostat (Ankaferd Blood Stopper®, ABS)- induced pharmacological modulation of essential erythroid proteins can cause vital erythroid aggregation via acting on fibrinogen gamma. Topical endoscopic ABS application is effective in
Externí odkaz:
https://doaj.org/article/efa6b80f17774ced878acc40642011ab
Autor:
Nur Soyer, İbrahim C Haznedaroğlu, Melda Cömert, Demet Çekdemir, Mehmet Yılmaz, Ali Ünal, Gülsüm Çağlıyan, Oktay Bilgir, Osman İlhan, Füsun Özdemirkıran, Emin Kaya, Fahri Şahin, Filiz Vural, Güray Saydam
Publikováno v:
Turkish Journal of Hematology, Vol 34, Iss 1, Pp 27-33 (2017)
Objective: Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia-negative malignancies characterized by a clonal proliferation of one or seve
Externí odkaz:
https://doaj.org/article/93b0b3f3366447f1a13c05b2c903eb80
Publikováno v:
Turkish Journal of Hematology, Vol 37, Iss 3, Pp 207-208 (2020)
Externí odkaz:
https://doaj.org/article/ccfd347b34094ffb9e73317ccf6c0847
Publikováno v:
Genetics & Applications, Vol 3, Iss 3 (2019)
Various anomalies of chromosome 1 which is the largest chromosome of the human karyotype were found in various hematologic diseases. In this retrospective study, clinical features and cytogenetic anomalies of 35 hematological patients with various ch
Externí odkaz:
https://doaj.org/article/cbe256d5d4af4bdf82a905ec01b1983f
Event-free Survival in Patients with Chronic Myeloid Leukemia Receiving Front-line Imatinib Mesylate
Autor:
Nesrin Damla Eyüpoğlu, Olgu Erkin Çınar, Salih Aksu, Yahya Büyükaşık, Nilgün Sayınalp, Haluk Demiroğlu, Hakan Göker, Osman İlhami Özcebe, İbrahim C. Haznedaroğlu
Publikováno v:
Acta Medica. 53:277-283
Objective: Chronic myeloid leukemia (CML) prognostication at the time of diagnosis is critical to determine the intensity of initial treatment. Event-free survival (EFS) has become a prominent concept of prognosis in the patients with chronic phase C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0409cd1bf03d164224b8e16f9d3fc77
https://doi.org/10.32552/2022.actamedica.745
https://doi.org/10.32552/2022.actamedica.745